Back to Search
THOMAS O'REILLY, PHARM.D.
PHARM.D.
Pharmacist
NPI: 1053624825Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
PMID 18301895·Cancer Chemother Pharmacol·2008
4-observational
Systemic inflammation alters the inflammatory response in experimental lipopolysaccharide-induced meningitis.
PMID 17177970·Clin Exp Immunol·2007
7-preclinical
Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.
PMID 15948135·Prostate·2005
7-preclinical
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
PMID 15723258·Cancer Chemother Pharmacol·2005
7-preclinical
Levels of nicotinamide adenine dinucleotide in extracellular body fluids of pigs may be growth-limiting for Actinobacillus pleuropneumoniae and Haemophilus parasuis.
PMID 12889731·Can J Vet Res·2003
7-preclinical
Effects of ankle-foot orthoses for children with hemiplegia on weight-bearing and functional ability.
PMID 19680063·Pediatr Phys Ther·2009
8-other
Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
PMID 19234060·Exp Biol Med (Maywood)·2009
7-preclinical
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
PMID 19223496·Clin Cancer Res·2009
4-observational
Dispensary level pilot implementation of rapid diagnostic tests: an evaluation of RDT acceptance and usage by providers and patients--Tanzania, 2005.
PMID 19019233·Malar J·2008
8-other
Where's the difficulty in standardized reading tests: the passage or the question?
PMID 19001391·Behav Res Methods·2008
8-other
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
PMID 18701483·Cancer Res·2008
7-preclinical
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
PMID 18332467·J Clin Oncol·2008
3-trial
Influence of the blood bacterial load on the meningeal inflammatory response in Streptococcus pneumoniae meningitis.
PMID 16643642·BMC Infect Dis·2006
4-observational
Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish.
PMID 16565716·Nat Chem Biol·2006
7-preclinical
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
PMID 16397235·Cancer Res·2006
7-preclinical
Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
PMID 16278399·Clin Cancer Res·2005
7-preclinical
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
PMID 16033851·Clin Cancer Res·2005
8-other
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
PMID 15958638·Clin Cancer Res·2005
7-preclinical
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
PMID 15797377·Cell·2005
8-other
Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
PMID 15542040·Bone·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3601 ROGERS RD
WAKE FOREST, NC 27587 - Phone
- (919) 453-0932
Quick Facts
- NPI
- 1053624825
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile